

In re Application of: Reed et al.

Application No: 10/047,991

Filed: January 14, 2002

For: Purification of Functional

Ribonucleoprotein Complexes

Examiner: Not yet assigned

Group Art Unit: 1645

Attorney Ref. No: HMV-080.01

U.S. Patent and Trademark Office Box Sequence, P.O. Box 2327 Arlington, VA 22202

## Certificate of First Class Mailing

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202, on the date set forth below.

May 10, 2002

Date of Signature and Mail Deposit

DANIEL MURRAY

## INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR § 1.97 (b)

Sir:

Submitted herewith on Form PTO-1449 is a listing of documents known to the Applicants and/or their attorney to be in compliance with the requirements of 37 CFR § 1.56 and 1.97(b). Copies of the references "CA" - "CJ" are also being submitted herewith.

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached Form 1449.

This submission does not represent that a search has been made or that no better art exists, nor does it constitute an admission that the cited documents are material or constitute "prior art." If the Examiner applies the listed documents as prior art against any claim in the

application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the referenced documents be applied against the claims of the present application.

Under 37 C.F.R. § 1.97(b)(3), this Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits; therefore, no fee is believed to be due in connection with the filing of this disclosure. If, however, a first Office Action on the merits issues in this application bearing a mailing date prior to the date of this Information Disclosure Statement, please charge the appropriate fees as required under 37 C.F.R. § 1.17(p) to our **Deposit Account No. 06-1448**.

Should there be any questions after reviewing this paper, the Examiner is invited to contact the undersigned at (617) 832-1000.

Respectfully Submitted,

May 10, 2002

Customer No. 25181
Patent Group
Foley, Hoag & Eliot LLP
One Post Office Square
Boston, MA 02109-2170

Isabelle M. Clauss, Ph.D.

Reg. No. 47,326

Attorney for Applicant

Sheet Page 1 of 2

orm PTO-1445		CITA	TION	Docket Number (Optional) HMV-080.01				Application Number 10/047,991			
INFORMAT	ION E	ISCLOSURE CITA PELICATION	HON	Applicant Reed et al.							
IN AND PELICATION (Userse veral sheets if Recussary)				Filing Date January 14, 2002				Group Art Unit			
	HAM	14 000 5		U.S. P	ATENT DOCUMENT	rs					
EXAMINER \ INITIAL	OCUMENTAL MBER		DAT		NAME		CLASS		FILING DATE IF APPROPRIATE		
	AA										
				FOREIG	N PATENT DOCUM	ENTS					
	DOCUMENT NUMBER DA			COLDIEDA		CLA	ASS	SUBCLASS	Translat YES	NO	
	ВА										
										-	
	11										
				OCUMEN	TMC	(Includ	ing Auth	or, Title, Date, Pe	rtinent Pages E	itc.)	
	CA				ling of R17 Coat Protein to RNA			ome Complexes, C	GENES & DEV	EL.	
	СВ	6:1986.									
	СС	Complex (E) in Mamm	als, GENE	S & DEVEL.							
	CD	Catalytic Step II of the	Splicing R	eaction, Eivin							
	CE	Carey, J. et al. (1983),	Sequence-	Specific Inter-	action of R17 Coat Protein with	its Ribonucleic A	cid Bind	ing Site, BIOCHE	EM. 22(10):260	1.	
	CF				re-Messenger-RNA Splicing to I						
	CG	ACIDS RES. 18(22):6	ckens, M. 587.	(1990), Purifi	cation of RNA and RNA-Proteir	n Complexes by a	n R17 Co	oat Protein Affinit	y Method, NU	CLEIC	
	СН	l .	Pre-mRNA	Splicing and	d mRNA Export Linked by Direc	et Interactions Be	tween U	AP56 and Aly, NA	ATURE 413:64	4.	
	CI		, T. (1993)	, A Splicing	Enhancer Complex Controls Alt	ernative Splicing	of Doubl	esex Pre-mRNA,	CELL 74:105.		

Sheet Page 2 of 2 Application Number 10/047,991 Docket Number (Optional) HMV-080.01 Form PTO-14 INFORMATION DISCLOSURE CITATION Applicant IN AN APPLICATION Reed et al. (Use several sheets if necessary) Filing Date January 14, 2002 Group Art Unit (2008), Functional Association of U2 snRNP with the ATP-Independent Splicesomal Complex E, MOLECULAR CELL 5:779.

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in

conformance and not considered. Include copy of this form with next communication to the applicant.

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

DATE CONSIDERED

**EXAMINER**